The DOI matches its Crossref record; 157 of the 162 references it cites were found in a registry or an index.
RAS Proteins and Their Regulators in Human Disease
Open accessAbstract
RAS proteins are binary switches, cycling between ON and OFF states during signal transduction. These switches are normally tightly controlled, but in RAS-related diseases, such as cancer, RASopathies, and many psychiatric disorders, mutations in the RAS genes or their regulators render RAS proteins persistently active. The structural basis of the switch and many of the pathways that RAS controls are well known, but the precise mechanisms by which RAS proteins function are less clear. All RAS biology occurs in membranes: a precise understanding of RAS' interaction with membranes is essential to understand RAS action and to intervene in RAS-driven diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, farnesylation at the position 185 cysteine residue results in KRAS anchoring at the plasma membrane, initiating the activation of KRAS and its downstream signaling42.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Post-translational modification of KRAS plays an important role in KRAS–MAPK pathway activation.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [42]
The cited source says what the claim attributes to it.
In the citing paper
“KRAS is one of the most frequently mutated oncogenes in cancer, yet efforts to directly target KRAS have been mostly unsuccessful because initial analyses of KRAS proteins indicated that they lack a clear pocket to which small molecules can bind with high affinity [1, 2].”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Although KRAS mutations are often collectively classified as a single oncogenic entity, distinct KRAS alleles exhibit substantial biochemical and functional heterogeneity [1,4,12].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [4]
In the citing paper
“Mutational activation of KRAS promotes the initiation and progression of cancers, especially in the colorectum, pancreas, lung, and blood plasma, with varying prevalence of specific activating missense mutations.”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [1]
In the citing paper
“However, it is frequently mutated in only a handful of cancers, with the highest frequencies in colorectal adenocarcinoma (COAD), lung adenocarcinoma (LUAD), multiple myeloma (MM), and pancreatic adenocarcinoma (PAAD).”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [1]
In the citing paper
“KRAS is one of the most commonly mutated genes in cancer1,2”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [1]
In the citing paper
“When mutated at one of its four hotspot codons—12, 13, 61, or 146—activated KRAS protein hyperactivates many downstream effector pathways, such as the MAPK and PI3K-AKT signaling pathways1”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [1]
In the citing paper
“As protein tyrosine phosphorylation plays an essential role in multiple intracellular processes, SHP2 is involved in the regulation of multiple signaling pathways, including those involved in cancer cells, such as RAS-MAPK, PI3K-AKT and JAK-STAT pathways.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [261]
In the citing paper
“RAS acts as a molecular switch, transmitting signals of cell growth and differentiation by binding to GTP or GDP and switching between active and inactive states.261”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [261]
In the citing paper
“abnormalities in components of the RAS pathway, including activating RAS mutations, are common across a diverse range of malignancies”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [4]
In the citing paper
“The RAS family GTPases, KRAS, NRAS and HRAS, cycle between GTP-loaded ‘on’ and GDP-loaded ‘off’ states4,6, involving the action of RAS-guanine nucleotide exchange factors (RAS-GEFs) and RAS-GTPase-activating proteins (RAS-GAPs), respectively.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [4]
In the citing paper
“Almost all cancer-associated RAS mutations (~95%) affect codon 12, 13 or 61, and lead to a markedly increased basal RAS-GTP:RAS-GDP ratio and constitutive activation of RAS effectors4,6.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [4]
In the citing paper
“When mutated, oncogenic RAS remains preferentially in the active GTP-bound state, whereas GTP hydrolysis by its GTPase function and enzymes such as GTPase-activating proteins, is compromised1,2.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [1]
In the citing paper
“KRAS in particular, is among the most frequently mutated oncogenes in cancer and is commonly associated with therapeutic resistance and poor prognosis1,5,6.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [1]
In the citing paper
“These mutations dramatically shift the equilibrium of Ras protein to exist mostly in the GTP-bound state and effectively uncouple Ras proteins from upstream receptor inputs and drive constitutive signaling to downstream Ras effector pathways (13).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [13]
In the citing paper
“On the one hand, the affinity of KRAS and GTP is at the pM level, while the concentration of GTP in cells is up to 0.5 μM.”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [18]
In the citing paper
“It is difficult to achieve effective competition like protein kinase inhibitors [18, 19].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [18]
In the citing paper
“Oncogenic KRAS can activate various downstream effector pathways, and the best characterized are phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinases (MAPK) (23–25).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [24]
In the citing paper
“we recognize that these elements have a substantial influence on KRAS dynamics [53,54] and signaling [55].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
GEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
All ras proteins are polyisoprenylated but only some are palmitoylated
Hancock, J. F., Magee, A. I., Childs, J. E., & Marshall, C. J. (1989) · Cell · doi:10.1016/0092-8674(89)90054-8 · Cited by 1,775
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
Regulation of Small GTPases by GEFs, GAPs, and GDIs
Cherfils, J., & Zeghouf, M. (2013) · Physiological Reviews · doi:10.1152/physrev.00003.2012 · Cited by 1,245
A Cytoplasmic Protein Stimulates Normal N- ras p21 GTPase, But Does Not Affect Oncogenic Mutants
Trahey, M., & McCormick, F. (1987) · Science · doi:10.1126/science.2821624 · Cited by 1,211
Self-citationDistinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics · doi:10.1038/ng.3564 · Cited by 1,200
Milburn, M. V., Tong, L., deVos, A. M., Brünger, A. T., Yamaizumi, Z., Nishimura, S., & Kim, S. (1990) · Science · doi:10.1126/science.2406906 · Cited by 1,062
Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
Leevers, S. J., Paterson, H. F., & Marshall, C. J. (1994) · Nature · doi:10.1038/369411a0 · Cited by 1,011
Flagged first, then by citations
5 of the 162 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 701–800 of 1,005
Reynolds, G., Gazzin, A., Carli, D., Massuras, S., Cardaropoli, S., Luca, M., Defilippi, B., Tartaglia, M., Ferrero, G. B., & Mussa, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083515 · Cited by 22
Advances in i-motif structures: Stability, gene expression, and therapeutic applications
Wu, M., Liu, Y., Zhu, X., Zhang, X., Kong, Q., Lu, W., Yuan, X. F., Liu, Y., Liu, Y., Lu, K., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143555 · Cited by 19
Marasco, M., Kumar, D., Borrego, S. G., Seale, T. S., Maddalena, G., Mezzadra, R., Belanger, K., Cole, S., Perez, B., Luan, W., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0614 · Cited by 17
Targeting the KRAS Oncogene for Patients with Metastatic Colorectal Cancer
Miao, R., Yu, J. B., & Kim, R. D. (2025) · Cancers · doi:10.3390/cancers17091512 · Cited by 19
Dual Targeting of EGFR and IGF1R in the TNFAIP8 Knockdown Non–Small Cell Lung Cancer Cells
Day, T. F., Kallakury, B., Ross, J. S., Voronel, O., Vaidya, S., Sheehan, C. E., & Kasid, U. N. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0731 · Cited by 17
Proteins moonlighting in tumor metabolism and epigenetics
Lv, L., & Lei, Q. (2021) · Frontiers of Medicine · doi:10.1007/s11684-020-0818-1 · Cited by 18
Oncogenic Ras Disrupts Epithelial Integrity by Activating the Transmembrane Serine Protease Hepsin
Tervonen, T. A., Pant, S. M., Belitškin, D., Englund, J. I., Närhi, K. M., Haglund, C. H., Kovanen, P. E., Verschuren, E. W., & Klefström, J. T. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1760 · Cited by 17
Discovery of a dual Ras and ARF6 inhibitor from a GPCR endocytosis screen
Giubilaro, J., Schuetz, D. A., Stępniewski, T. M., Namkung, Y., Khoury, E., Lara‐Márquez, M., Campbell, S. L., Beautrait, A., Armando, S., Radresa, O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24968-y · Cited by 17
Targeting KRAS G12C mutation in lung adenocarcinoma
Rohatgi, A., & Govindan, R. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.12.021 · Cited by 17
Pearson, A. D. J., Allen, C. E., Fangusaro, J., Hutter, C., Witt, O., Weiner, S. L., Reaman, G. H., Russo, M., Bandopadhayay, P., Ahsan, S., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.09.036 · Cited by 17
Frost, M. G., Jensen, K. J., Gotfredsen, D. R., Sørensen, A. M. S., Ankarfeldt, M. Z., Louie, K. S., Sroczynski, N., Jakobsen, E. H., Andersen, J. L., Jimenez‐Solem, E., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2023.02.021 · Cited by 17
Lee, K., Ikura, M., & Marshall, C. B. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202218698 · Cited by 17
Bagherpoor, A. J., Shameem, M., Luo, X., Seelig, D. M., & Kassie, F. (2023) · Carcinogenesis · doi:10.1093/carcin/bgad020 · Cited by 17
Hosseini, S. S., Nazifi, P., Amini, M. A., Zargari, F., Yari, A. H., Baradaran, B., Mahboob, S., & Mokhtarzadeh, A. (2023) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520623666230718145100 · Cited by 17
Guo, J., Ke, S., Chen, Q., Zhou, J., Guo, J., & Qiu, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411584 · Cited by 17
Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions
Shang, Y., Fu, S., Hao, Q., Ying, H., Wang, J., & Shen, T. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107092 · Cited by 17
K128 ubiquitination constrains RAS activity by expanding its binding interface with GAP proteins
Magits, W., Steklov, M. Y., Jang, H., Sewduth, R. N., Florentin, A., Lechat, B., Sheryazdanova, A., Zhang, M., Šimíček, M., Prag, G., et al. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00146-w · Cited by 17
Liu, Z., Yang, L., Liu, C., Wang, Z., Xu, W., Lu, J., Wang, C., & Xu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1371829 · Cited by 17
Robust and inducible genome editing via an all-in-one prime editor in human pluripotent stem cells
Wu, Y., Zhong, A., Sidharta, M., Kim, T. W., Ramirez, B., Persily, B., Studer, L., & Zhou, T. (2024) · Nature Communications · doi:10.1038/s41467-024-55104-1 · Cited by 22
Liu, Y., Chen, J., Li, X., Fan, Y., Peng, C. Y., Ye, X., Wang, Y. A., & Xie, X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107577 · Cited by 17
Plasma membrane-associated ARAF condensates fuel RAS-related cancer drug resistance
Li, W., Shi, X., Tan, C., Jiang, Z., Li, M., Ji, Z., Zhou, J., Luo, M., Fan, Z., Ding, Z., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-024-01826-8 · Cited by 17
Ganaie, A. A., Siddique, H. R., SHEIKH, I. A., Parray, A., Wang, L., Panyam, J., Villalta, P. W., Deng, Y., Konety, B. R., & Saleem, M. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23200 · Cited by 17
Lai, C., Wu, F., Wang, Y., Wang, W., Li, Y., Zhang, G., Gao, J., Zhu, Z., Yuan, J., Yang, J., et al. (2020) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2020.111453 · Cited by 17
The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer
Moerland, J. A., Zhang, D., Reich, L. A., Carapellucci, S., Lockwood, B., Leal, A. S., Krieger-Burke, T., Aleiwi, B., Ellsworth, E. L., & Liby, K. T. (2020) · Scientific Reports · doi:10.1038/s41598-020-79260-8 · Cited by 17
Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients
Jacobs, F., Cani, M., Malapelle, U., Novello, S., Napoli, V. M., & Bironzo, P. (2021) · Cancers · doi:10.3390/cancers13246332 · Cited by 18
Saliani, M., Jalal, R., & Javadmanesh, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-11697-5 · Cited by 17
Explaining Conformational Diversity in Protein Families through Molecular Motions
Lombard, V., Grudinin, S., & Laine, É. (2024) · Scientific Data · doi:10.1038/s41597-024-03524-5 · Cited by 20
Becker, J. H., Metropulos, A. E., Spaulding, C., Marinelarena, A. M., Shields, M. A., Principe, D. R., Pham, T. D., & Munshi, H. G. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3574 · Cited by 17
Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor
Ye, Q., Shvartsbart, A., Li, Z., Gan, P., Policarpo, R. L., Qi, C., Roach, J. J., Zhu, W., McCammant, M. S., Hu, B., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02662 · Cited by 17
Structural basis for LZTR1 recognition of RAS GTPases for degradation
Dharmaiah, S., Bonsor, D. A., Mo, S., Fernandez-Cabrera, A., Chan, A. H., Messing, S., Drew, M. R., Vega, M., Nissley, D. V., Esposito, D., et al. (2025) · Science · doi:10.1126/science.adv7088 · Cited by 16
Self-citationNeuron type-specific expression of a mutant KRAS impairs hippocampal-dependent learning and memory
Ryu, H.-H., Kang, M., Hwang, K., Jang, H. B., Kim, S. J., & Lee, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-74610-y · Cited by 16
Liver regeneration biology: Implications for liver tumour therapies
Hadjittofi, C., Feretis, M., Martin, J. L., Harper, S., & Huguet, E. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i12.1101 · Cited by 18
Carotenoids from Marine Sources as a New Approach in Neuroplasticity Enhancement
Pietrasik, S., Cichoń, N., Bijak, M., Gorniak, L., & Saluk, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23041990 · Cited by 16
G-Protein Phosphorylation: Aspects of Binding Specificity and Function in the Plant Kingdom
Oliveira, C. C., Jones, A. M., Fontes, E. P. B., & Reis, P. A. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126544 · Cited by 16
Conquering oncogenic KRAS and its bypass mechanisms
Hou, P., & Wang, Y. (2022) · Theranostics · doi:10.7150/thno.71260 · Cited by 18
Mutant KRAS regulates transposable element RNA and innate immunity via KRAB zinc-finger genes
Reggiardo, R. E., Maroli, S. V., Halasz, H., Ozen, M. O., Hrabeta‐Robinson, E., Behera, A. K., Peddu, V., Carrillo, D., LaMontagne, E., Whitehead, L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111104 · Cited by 24
Site-Specific Activity-Based Protein Profiling Using Phosphonate Handles
van Bergen, W., Hevler, J. F., Wu, W., Baggelaar, M. P., & Heck, A. J. R. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100455 · Cited by 16
Tumor cells fail to present MHC-II–restricted epitopes derived from oncogenes to CD4+ T cells
Brightman, S. E., Naradikian, M. S., Thota, R. R., Becker, A., Montero, L., Bahmanof, M., Premlal, A. L. R., Greenbaum, J., Peters, B., Cohen, E. E. W., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.165570 · Cited by 17
Selected Approaches to Disrupting Protein–Protein Interactions within the MAPK/RAS Pathway
Harwood, S. J., Smith, C. R., Lawson, J. D., & Ketcham, J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087373 · Cited by 17
Methylation of KRAS by SETD7 promotes KRAS degradation in non-small cell lung cancer
Chiang, C.-Y., Fan, S., Zheng, H., Guo, W., Zheng, Z., Sun, Y., Zhong, C., Zeng, J., Li, S., Zhang, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113003 · Cited by 16
Choi, J., Shin, J. H., Kim, T. K., Kim, K., Kim, J.-Y., Jeon, E., Park, J., Han, Y. D., Kim, K., Sim, T., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216904 · Cited by 19
Ionizable lipid nanoparticles for RAS protease delivery to inhibit cancer cell proliferation
Atsavapranee, E., Haley, R. M., Billingsley, M. M., Chan, A., Ruan, B., Figueroa‐Espada, C. G., Gong, N., Mukalel, A. J., Bryan, P. N., & Mitchell, M. J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.05.015 · Cited by 16
Molecular glue degrader for tumor treatment
Hu, Y., Yan, Y., Wang, J., Hou, J., & Lin, Q. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1512666 · Cited by 17
Gliding Basal Cell Migration of the Urothelium during Wound Healing
Sano, T., Kobayashi, T., Ogawa, O., & Matsuda, M. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.07.010 · Cited by 16
Patterning of Oncogenic Ras Clustering in Live Cells Using Vertically Aligned Nanostructure Arrays
Mu, H., Zeng, Y., Zhuang, Y., Gao, W., Zhou, Y., Rajalingam, K., & Zhao, W. (2022) · Nano Letters · doi:10.1021/acs.nanolett.1c03886 · Cited by 15
Lu, H., & Martı́, J. (2022) · Nanoscale · doi:10.1039/d1nr07622a · Cited by 14
Wang, C.-X., Wang, T., Zhang, K.-D., Li, M., Shen, Q., Lu, S., & Zhang, J. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00897-4 · Cited by 16
Whaby, M., Wallon, L., Mazzei, M., Khan, I., Teng, K. W., Koide, S., & O’Bryan, J. P. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102661 · Cited by 17
Activation of Rho Family GTPases by Small Molecules
Palsuledesai, C. C., Surviladze, Z., Waller, A., Miscioscia, T. F., Guo, Y., Wu, Y., Strouse, J., Romero, E., Salas, V. M., Curpan, R. F., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00038 · Cited by 18
Maxeiner, S., Grolleman, J. E., Schmid, T., Kammenga, J. E., & Hajnal, A. (2019) · Life Science Alliance · doi:10.26508/lsa.201800255 · Cited by 15
Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants
Post, J. B., Roodhart, J. M. L., & Snippert, H. J. G. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.005 · Cited by 16
Chang, Y., Hsu, C., Tang, C.-W., Chen, X., Huang, H., & Juan, H. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra120.002219 · Cited by 15
Maruyama, K., Shimizu, Y., Nomura, Y., Oh-hara, T., Takahashi, Y., Nagayama, S., Fujita, N., & Katayama, R. (2025) · npj Precision Oncology · doi:10.1038/s41698-024-00793-6 · Cited by 16
Cui, X., Huang, T., Jiang, T., & Wang, H. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217540 · Cited by 18
Ge, J., Cai, J., Zhang, G., Li, D., & Tao, L. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06711-z · Cited by 16
Copper-induced cell death mechanisms and their role in the tumor microenvironment
Jiao, Y., Wang, H., Zhu, M., Liu, T., Li, Y., Yang, S., Zhang, M., & Zhang, L. (2025) · Frontiers in Cell Death · doi:10.3389/fceld.2025.1628470 · Cited by 16
Identification of a Highly Cooperative PROTAC Degrader Targeting GTP-Loaded KRAS(On) Alleles
Vetma, V., Puoti, I., Karolak, N. K., Chakraborti, S., Diers, E., Girardi, E., Khan, S., Kidd, G., Kropatsch, K., McLennan, R., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c10354 · Cited by 17
Expanding TOR Complex 2 Signaling: Emerging Regulators and New Connections
An, P., Xu, W., Luo, J., & Luo, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.713806 · Cited by 15
Liang, T.-L., Li, R., Mai, C.-T., Guan, X., Li, J., Wang, X., Ma, L.-R., Zhang, F., Wang, J., He, F., et al. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153831 · Cited by 14
Su, X., Chen, D., Zhu, L., Hao, J., Cai, J., Li, P., Han, B., Wang, D., Li, H., Fan, J., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04598-y · Cited by 16
Roux, Ö. L., Pershing, N. L., Kaltenbrun, E., Newman, N. J., Everitt, J. I., Baldelli, E., Pierobon, M., Petricoin, E. F., & Counter, C. M. (2022) · eLife · doi:10.7554/elife.75715 · Cited by 15
Oyedele, A.-Q. K., Ogunlana, A. T., Boyenle, I. D., Ibrahim, N. O., Gbadebo, I. O., Owolabi, N., Ashiru, M. A., Francis, A. C., Eyinade, O., & Adelusi, T. I. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10534-1 · Cited by 17
Ras superfamily GTPase activating proteins in cancer: Potential therapeutic targets?
Xiao, H., Wang, G., Zhao, M., Wen, S., Ouyang, L., & Sun, Q. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115104 · Cited by 18
Yang, J., Li, S., He, J., Xu, Q., Xie, M., Yang, C., Wang, H., Zhang, Y., Wan, Q., & Xiang, M. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01405-1 · Cited by 17
Ikari, M., Yagi, H., Kasai, T., Inomata, K., Ito, M., Higuchi, K., Matsuda, N., Ito, Y., & Kigawa, T. (2023) · JACS Au · doi:10.1021/jacsau.3c00108 · Cited by 15
Nazari, M. H. D., Shahrokh, S., Ghanbari-Maman, L., Maleknia, S., Ghorbaninejad, M., & Meyfour, A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21154 · Cited by 16
Li, M., Dai, L.-T., Gao, Z.-Y., Yan, J.-T., Xu, S., Tan, J., Huang, Z., Chen, S.-B., & Chen, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01773 · Cited by 15
Conditional Cooperativity in RAS Assembly Pathways on Nanodiscs and Altered GTPase Cycling
Lee, S., & Lee, K. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202316942 · Cited by 15
Thomas, Q. D., Quantin, X., Lemercier, P., CHOUAID, C., Schneider, S., Filleron, T., Remon-Masip, J., Pérol, M., Debieuvre, D., Audigier-Valette, C., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103473 · Cited by 15
Miao, Y., Bai, Y., Miao, J., Murray, A. A., Lin, J., Dong, J., Qu, Z., Zhang, R., Nguyen, Q. D., Wang, S., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci177142 · Cited by 17
SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers
Lilja, J., Kaivola, J., Conway, J. R. W., Vuorio, J., Parkkola, H., Roivas, P., Dibus, M., Chastney, M. R., Varila, T., Jacquemet, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52326-1 · Cited by 14
Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia
Chen, Y., Yin, Z., Westover, K. D., Zhou, Z., & Shu, L. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0504 · Cited by 15
A novel micelleplex for tumour-targeted delivery of CRISPR-Cas9 against KRAS-mutated lung cancer
Chen, S., Triki, M., Carneiro, S. P., & Merkel, O. M. (2025) · Nanoscale · doi:10.1039/d4nr03471f · Cited by 15
Campbell, S., Franks, C. E., Borne, A. L., Shin, M., Zhang, L., & Hsu, K. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.113001 · Cited by 15
Orai1 Promotes Osteosarcoma Metastasis by Activating the Ras-Rac1-WAVE2 Signaling Pathway
Guo, Y., Zhu, J., Wang, X., Li, R., Jiang, K., Chen, S., Fan, J., Xue, L., & Hao, D. (2019) · Medical Science Monitor · doi:10.12659/msm.919594 · Cited by 15
Proteasome regulation by reversible tyrosine phosphorylation at the membrane
Chen, L., Zhang, Y., Shu, X., Chen, Q., Wei, T., Wang, H., Wang, X., Wu, Q., Zhang, X., Liu, X., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01674-z · Cited by 15
Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis
Khan, I., MarElia, C. B., Lefler, J. E., Zuberi, M., Denbaum, E., Koide, A., Connor, D. M., Broome, A., Pécot, T., Timmers, C. D., et al. (2021) · Small GTPases · doi:10.1080/21541248.2021.1906621 · Cited by 14
Gene expression profile analysis of gallic acid-induced cell death process
Tang, H. M., & Cheung, P. C. K. (2021) · Scientific Reports · doi:10.1038/s41598-021-96174-1 · Cited by 17
Signaling Pathways that Regulate Macropinocytosis in Mammalian Cells
Palm, W. (2022) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-94004-1_8 · Cited by 16
Wang, Q., Wu, S., Gu, Y., Liang, H., He, F., Wang, X., He, D., & Wu, K. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01069-3 · Cited by 15
Genetics of brain arteriovenous malformations and cerebral cavernous malformations
Hongo, H., Miyawaki, S., Teranishi, Y., Ishigami, D., Ohara, K., Sakai, Y., Shimada, D., Umekawa, M., Koizumi, S., Ono, H., et al. (2022) · Journal of Human Genetics · doi:10.1038/s10038-022-01063-8 · Cited by 16
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun
Bungaro, M., Novello, S., & Passiglia, F. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01033-4 · Cited by 15
Ding, H., Yu, X., Yu, Y., Lao, X., Chen, H., Gao, K., Jia, Y., & Yan, Z. (2020) · Oncology Reports · doi:10.3892/or.2020.7470 · Cited by 15
Association of KRAS mutation with tumor deposit status and overall survival of colorectal cancer
Zhang, M., Hu, W., Hu, K., Lin, Y., Feng, Z., Yun, J., Gao, N., & Zhang, L. (2020) · Cancer Causes & Control · doi:10.1007/s10552-020-01313-0 · Cited by 15
Swimming toward solutions: Using fish and frogs as models for understanding RASopathies
Patterson, V. L., & Burdine, R. D. (2020) · Birth Defects Research · doi:10.1002/bdr2.1707 · Cited by 16
NMR in integrated biophysical drug discovery for RAS: past, present, and future
Marshall, C. B., KleinJan, F., Gebregiworgis, T., Lee, K., Fang, Z., Eves, B. J., Liu, N. F., Gasmi-Seabrook, G. M. C., Enomoto, M., & Ikura, M. (2020) · Journal of Biomolecular NMR · doi:10.1007/s10858-020-00338-6 · Cited by 15
Ma, C., Yan, Y., Xu, L., Tu, W., Chen, F., & Wang, J. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29155 · Cited by 14
Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico
Fleischmann, J., Feichtner, A., DeFalco, L., Kugler, V., Schwaighofer, S., Huber, R. G., & Stefan, E. (2021) · Biomolecules · doi:10.3390/biom11040518 · Cited by 12
Imaizumi, T., Akaiwa, M., Abe, T., Nigawara, T., Koike, T., Satake, Y., Watanabe, K., Kaneko, O., Amano, Y., Mori, K., et al. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116949 · Cited by 14
Shi, S., Zheng, L., Ren, Y., & Wang, Z. (2023) · Molecules · doi:10.3390/molecules28072886 · Cited by 13
Zaremba, A., Mohr, P., Gutzmer, R., Meier, F. E., Pföhler, C., Weichenthal, M., Terheyden, P. A. M., Forschner, A., Leiter, U., Ulrich, J., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.04.008 · Cited by 13
Guo, Z., Xie, Q., Wu, Y., Mo, H., Zhang, J., He, G., Li, Z., Gan, L., Feng, L., Li, T., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00814-9 · Cited by 14
Reduced dynamic complexity allows structure elucidation of an excited state of KRASG13D
Chao, F.-A., Chan, A. H., Dharmaiah, S., Schwieters, C. D., Tran, T. H., Taylor, T. E., Ramakrishnan, N., Esposito, D., Nissley, D. V., McCormick, F. P., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04960-6 · Cited by 15
Self-citationWang, Y., Wang, X. D., Tang, T., Xie, Y., Li, J., Wang, W., Li, T., Liu, D. X., Yang, K., Shi, Y., et al. (2023) · Fitoterapia · doi:10.1016/j.fitote.2023.105744 · Cited by 15
Cheng, C., Hou, K., Hsu, C., & Chiang, L. (2023) · Advanced Science · doi:10.1002/advs.202304926 · Cited by 14
Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations
Linette, G. P., Bear, A. S., & Carreno, B. M. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1212 · Cited by 14
Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node
Scardaci, R., Berlinska, E., Scaparone, P., Michelina, S. V., Garbo, E., Novello, S., Santamarı́a, D., & Ambrogio, C. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13605 · Cited by 14
Metformin combined with CB-839 specifically inhibits KRAS-mutant ovarian cancer
Wu, H., Zhang, J., Wang, Q., Li, Z., Li, L., & Xie, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-90963-8 · Cited by 14
Pathogenesis of non-hereditary brain arteriovenous malformation and therapeutic implications
Ota, T., & Komiyama, M. (2020) · Interventional Neuroradiology · doi:10.1177/1591019920901931 · Cited by 16
Chan, M. H., Aminzai, S., Hu, T., Taran, A., Li, S., Kim, C., Pilz, R. B., & Casteel, D. E. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010984 · Cited by 14
Metadata
- Authors
- Simanshu, D. K., Nissley, D. V., & McCormick, F.
- Affiliations
- Frederick National Laboratory for Cancer Research (US)
- University of California, San Francisco (US)
- Corresponding author
- McCormick, Frank
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 170
- Issue
- 1
- Pages
- 17-33
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC5555610
- OpenAlex
- W2732767128
- Cited by
- 1,943
- References
- 162
- Citations by year
- 2026: 210 · 2025: 263 · 2024: 276 · 2023: 247 · 2022: 267 · 2021: 247 · 2020: 194 · 2019: 143 · 2018: 82 · 2017: 12
- FWCI
- 11.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute
- NIH (HHSN261200800001E)
- Outstanding Investigator Award (5R35CA197709)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- Ras proteins, Ras signaling, RASopathies, cancer, mental illness, RAS mutations, signal transduction, membrane binding, Ras activation
- MeSH terms
- Congenital Abnormalities, Animals, Mental Disorders, Cell Membrane, Humans, Mutation, Neoplasms, Phylogeny, Yeasts, Signal Transduction, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
